FDA Approves Elahere to Treat Platinum-Resistant Ovarian Cancer
One of the many difficulties in managing ovarian cancer is the treatment of platinum resistant cancer i.e. recurrence of cancer within 6 months after initial therapy.
The FDA has recently approved the use of Elahere an antibody-drug conjugate that targets the cancer by attaching to a commonly found cell surface protein (Folate Receptor Alpha; FR𝛂), thereby enabling cytotoxic access.
FR𝛂 is found in 45% of all platinum resistant ovarian cancers. The approval followed the improved survival shown in the SORAYA trial with better response and duration of effect. The principal side effects include ocular toxicity, nausea and marrow suppression. This new treatment, the first approved by the FDA since 2014 helps in the management of a challenging condition.
No comments:
Post a Comment